Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).

Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use Biomarkers, Tumor / blood CA-125 Antigen / blood Carboplatin / therapeutic use Circulating MicroRNA / blood Cytoreduction Surgical Procedures Female Humans Indoles / therapeutic use Kinetics Membrane Proteins / blood Middle Aged Neoadjuvant Therapy Ovarian Neoplasms / blood Paclitaxel / therapeutic use Predictive Value of Tests Prognosis Progression-Free Survival Response Evaluation Criteria in Solid Tumors

Biomarkers Chemotherapy Ovarian cancer Prognosis ca125 miRNA

Journal

Gynecologic oncology

ISSN: 1095-6859

Titre abrégé: Gynecol Oncol

Pays: United States

ID NLM: 0365304

Informations de publication

Date de publication:
10 2020

Historique:

received: 21 05 2020

accepted: 11 07 2020

pubmed: 28 7 2020

medline: 15 4 2021

entrez: 27 7 2020

Statut: ppublish

Résumé

MicroRNAs (miRNAs) are promising biomarkers in ovarian cancer. Their kinetics during treatment might be useful for monitoring disease burden, and guiding treatments in patients treated with peri-operative chemotherapy and interval debulking surgery (IDS). Serial blood samples of patients enrolled in the randomized phase II CHIVA trial, comparing first line carboplatin-paclitaxel +/- nintedanib (NCT01583322) and IDS, were investigated to assess the kinetics of 11 relevant miRNAs. Their prognostic/predictive values regarding the likelihood of complete IDS, and the patient survival, were assessed and compared to those of CA125 kinetics. The selection of the miRNAs (miR-15b-5p, miR-16-5p, miR-20a-5p, miR-21-5p, miR-93-5p, miR-122-5p, miR-150-5p, miR-195-5p, miR-200b-3p, miR-148b-5p and miR-34a-5p) was based on the expression levels found with a large explorative panel, and on the literature data. 756 serial blood samples from 119 patients were analyzed for a total of 8172 miRNA assays, and 1299 CA125 values. The longitudinal kinetics of the miRNA expressions were highly inconsistent, and were not related to CA125 dynamics. The miRNA changes during neoadjuvant treatment were not found associated with RECIST tumor response or IDS outcomes. Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (p = .009) and OS benefits (p < .001), respectively, using univariate tests. The longitudinal kinetics of miRNA expressions during neoadjuvant treatment in ovarian cancer patients were inconsistent, and were not found to be associated with tumor burden changes. Although some prognostic value could be discussed, no predictive value regarding tumor responses or IDS quality could be identified.

Identifiants

DOI: 10.1016/j.ygyno.2020.07.021 PMID: 32712155

pubmed: 32712155

pii: S0090-8258(20)33656-8

doi: 10.1016/j.ygyno.2020.07.021

pii:

doi:

Substances chimiques

Biomarkers, Tumor 0

CA-125 Antigen 0

Circulating MicroRNA 0

Indoles 0

MUC16 protein, human 0

Membrane Proteins 0

Carboplatin BG3F62OND5

nintedanib G6HRD2P839

Paclitaxel P88XT4IS4D

Banques de données

ClinicalTrials.gov

['NCT01583322']

Types de publication

Clinical Trial, Phase II Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

256-263

Informations de copyright

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no potential conflicts of interest.